CSL Limited (CSL.AX)
| Previous close | 277.05 |
| Open | 276.86 |
| Bid | 279.00 x 13700 |
| Ask | 280.59 x 21700 |
| Day's range | 276.02 - 280.43 |
| 52-week range | 228.65 - 312.99 |
| Volume | |
| Avg. volume | 687,062 |
| Market cap | 134.915B |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | 36.12 |
| EPS (TTM) | 7.73 |
| Earnings date | 13 Feb 2024 |
| Forward dividend & yield | 3.81 (1.36%) |
| Ex-dividend date | 11 Mar 2024 |
| 1y target est | 303.42 |
PR NewswireRecently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons
CSL Seqirus, a business of CSL (ASX: CSL), today announced a real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID), showing that a cell-based quadrivalent influenza vaccine (QIVc) prevented more test-confirmed influenza cases among individuals 4–64 years of age compared with the egg-based quadrivalent influenza vaccine (QIVe) over three consecutive U.S. influenza seasons (2017–2020).1 These data add to the growing wealth of evidence supporting the benefits o
GlobeNewswireMark Cuban Foundation and CSL Bring AI Bootcamp to Philadelphia Teens
Applications for camp that offers free world-class AI education to help prepare students for latest tech evolution are now openPHILADELPHIA, April 30, 2024 (GLOBE NEWSWIRE) -- The Mark Cuban Foundation, in partnership with CSL, is bringing the only artificial intelligence (AI) camp of its kind, free of charge, to high school students in Philadelphia. With a custom and highly-relevant curriculum focused on teaching students about the latest developments in the world of AI and Generative AI, the c
- GlobeNewswire
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat dose PK/PD study of neffy under NAC conditions and updated testing concerning nitrosamine levels Exclusive licensing deal for Australia and New Zealand with CSL Seqirus; CSL Seqirus will be responsible for applying for regulatory approval, reimbursement and commercialization of neffy. ARS Pharmaceutical
